Parse Biosciences has announced a strategic collaboration with Codebreaker Labs to develop and validate a groundbreaking platform capable of scaling whole transcriptome single-cell profiling and causal genomics. The partnership aims to address persistent challenges in mapping the functional impact of genetic variants by enabling the parallel testing of thousands of genetic variants and measuring their effects at single-cell resolution. By combining Codebreaker Labs’ advanced platform for synthetic biology and variant engineering with Parse Biosciences’ scalable and accessible Evercode™ single-cell sequencing technology, the two companies are building a powerful system designed to generate high-quality causal data. This data is essential for AI researchers, drug discovery teams, and clinical scientists seeking to understand the biological consequences of genetic variation. The integration of Codebreaker’s ability to design and synthesize complex genetic perturbations with Parse’s high-throughput, cost-effective single-cell analysis platform allows for large-scale functional genomics studies. This approach enables researchers to move beyond correlation and identify direct cause-and-effect relationships between genetic changes and cellular outcomes. The collaboration is expected to accelerate the pace of discovery in areas such as disease mechanism research, drug target validation, and precision medicine. By making it possible to test thousands of variants in a single experiment with single-cell resolution, the platform could significantly reduce the time and cost of functional genomics research. This development comes at a critical time in biomedical research, as the demand for high-resolution, causal data continues to grow. The ability to link genetic variation to specific cellular phenotypes at scale is key to advancing next-generation therapeutics and diagnostics. The partnership builds on Parse Biosciences’ recent achievements, including the launch of Evercode™ Whole Blood Fixation and a new FFPE-compatible barcoding technology that enables single-cell transcriptome analysis from archived tissue samples. These innovations, combined with the new collaboration, position the company as a leader in accessible, scalable single-cell genomics solutions.